FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Dextrose 50% Injection
Status: Currently in Shortage
»Date first posted: 01/13/2022
»Therapeutic Categories: Endocrinology/Metabolism; Gastroenterology; Pediatric

Expand all

Amphastar Pharmaceuticals, Inc./IMS (Reverified 05/06/2022)

Company Contact Information:
800-423-4136

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
25 g/50 mL (0.5 g/mL), syringe, 10 per carton (NDC 76329-3302-1) (old NDC 76329-3301-1) Backorder due to increase in demand Demand increase for the drug

Hospira, Inc. (Revised 05/10/2022)

Company Contact Information:
844-646-4398

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
25 g/50 mL (0.5 g/mL), plastic syringe, 10 per bundle (NDC 0409-7517-16) Next Delivery: May 2022; Estimated Recovery: December 2022 Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay

Pfizer Customer Letter dated March 4, 2022.

Other
25 g/50 mL (0.5 g/mL), glass syringe, 10 per bundle (NDC 0409-4902-34) Next Delivery: May 2022; Estimated Recovery: January 2023 Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay

Pfizer Customer Letter dated March 4, 2022.

Other
25 g/50 mL (0.5 g/mL), single dose vial, 25 per tray (NDC 0409-6648-02) Next Delivery: June 2022; Estimated Recovery: March 2023 Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay Other

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English